Aurinia Pharmaceuticals Inc.

NasdaqGM AUPH

Aurinia Pharmaceuticals Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -15.86%

Aurinia Pharmaceuticals Inc. Return on Capital Employed (ROCE) is -15.86% for the year ending December 31, 2023, a 36.65% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Aurinia Pharmaceuticals Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -25.04%, a 30.15% change year over year.
Aurinia Pharmaceuticals Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -35.85%, a -48.37% change year over year.
Aurinia Pharmaceuticals Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -24.16%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGM: AUPH

Aurinia Pharmaceuticals Inc.

CEO	Mr. Peter S. Greenleaf M.B.A.
IPO Date	Sept. 3, 2014
Location	Canada
Headquarters	4464 Markham Street
Employees	300
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key trends

Past 5 years